Additional Reduction in Intraocular Pressure Achieved with Latanoprost in Normal-Tension Glaucoma Patients Previously Treated with Unoprostone

Enoki, Miho; Saito, Jun; Hara, Masaya; Uchida, Tetsuya; Sagara, Takeshi; Nishida, Teruo

doi:10.1007/s10384-005-0334-5

Cited by 6 publications

(2 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Latanoprost shows superior IOP reduction compared with isopropyl unoprostone [16-18]. However, the launch of travoprost reduced the frequency of latanoprost prescription.…”

Section: Discussionmentioning

confidence: 99%

Changes in Trend of Newly Prescribed Anti-Glaucoma Medications in Recent Nine Years in a Japanese Local Community

Kashiwagi¹

2010

TOOPHTJ

View full text Add to dashboard Cite

Purpose:To investigate changes in the trend of anti-glaucoma ophthalmic solutions in 2000-2008 in a Japanese local community.Materials and Methods:The subjects of this study were patients with glaucoma who were registered in the database of the glaucoma clinic of University of Yamanashi Hospital or the database of the Association for Research in Supporting System of Chronic Diseases (ARSSCD). The trend of newly prescribed anti-glaucoma ophthalmic solutions from January 2000 through July 2008 was analyzed. Changes in the trend of anti-glaucoma ophthalmic solutions and the persistence of each anti-glaucoma ophthalmic solution were investigated.Results:A total of 1,955 glaucoma patients were enrolled. Mean intraocular pressure (IOP) significantly reduced by year (R2=0.7938, p<0.001). The number of new prescriptions for analysis in the study period was 7,831. Prostaglandin (PG) analogues accounted for approximately 40% of the prescriptions during the period, and were followed by beta-blockers and carbonic anhydrase inhibitors (CAIs). Those three anti-glaucoma ophthalmic solutions accounted for approximately 90% of all the prescriptions. Latanoprost showed the longest persistence among the anti-glaucoma ophthalmic solutions. The number of newly prescribed anti-glaucoma ophthalmic solutions gradually increased with time.Conclusions:PG analogues are the most frequently prescribed and latanoprost showed the longest persistence among the anti-glaucoma ophthalmic solutions. PG analogues, beta-blockers, and CAIs accounted for the majority of newly prescribed anti-glaucoma ophthalmic solutions. An increase in the number of newly prescribed anti-glaucoma ophthalmic solutions may contribute to further IOP reduction.

show abstract

“…Latanoprost shows superior IOP reduction compared with isopropyl unoprostone [16-18]. However, the launch of travoprost reduced the frequency of latanoprost prescription.…”

Section: Discussionmentioning

confidence: 99%

Changes in Trend of Newly Prescribed Anti-Glaucoma Medications in Recent Nine Years in a Japanese Local Community

Kashiwagi¹

2010

TOOPHTJ

View full text Add to dashboard Cite

show abstract

“…Most of these studies compared unoprostone with timolol and latanoprost as monotherapy. Many studies have documented the superior efficacy in IOP reduction of latanoprost compared with unoprostone in primary open angle glaucoma and normal tension glaucoma 52–59,63–66. Sponsel et al compared the IOP-lowering and hydrodynamic effects of unoprostone and latanoprost in paired eyes of 25 patients with open-angle glaucoma or ocular hypertension 59.…”

Section: Efficacymentioning

confidence: 99%

An evidence-based review of unoprostone isopropyl ophthalmic solution 0.15% for glaucoma: place in therapy

Fung¹,

Whitson

2014

OPTH

View full text Add to dashboard Cite

Glaucoma is a progressive, neurodegenerative optic nerve disease that can cause significant visual morbidity and affects over 60 million people worldwide. The only known modifiable risk factor for glaucoma at this time is elevated intraocular pressure (IOP), which may be treated with medications, laser therapy, and/or incisional surgery. Topical ocular medications are commonly used as first-line therapy for glaucoma, although side effects may limit their use. Unoprostone is a novel 22-carbon ocular hypotensive agent that may be advantageous in treating some patients with open angle glaucoma or ocular hypertension. Unlike the 20-carbon prostanoids, such as latanoprost, that lower IOP primarily through an increase in uveoscleral outflow, unoprostone may lower IOP through increased aqueous outflow via the conventional trabecular meshwork pathway. Although not as efficacious as other prostanoids, unoprostone is effective for IOP reduction both as monotherapy and adjunctive therapy with timolol. Unoprostone has decreased affinity for the prostaglandin F2α receptor, which may explain its well tolerated ocular and systemic side effect profile compared with other prostanoids.

show abstract

Glaucoma - Next Generation Therapeutics: Impossible to Possible

Adams¹,

Stacy

Rangaswamy

et al. 2018

Pharm Res

View full text Add to dashboard Cite

Additional Reduction in Intraocular Pressure Achieved with Latanoprost in Normal-Tension Glaucoma Patients Previously Treated with Unoprostone

Cited by 6 publications

References 19 publications

Changes in Trend of Newly Prescribed Anti-Glaucoma Medications in Recent Nine Years in a Japanese Local Community

Changes in Trend of Newly Prescribed Anti-Glaucoma Medications in Recent Nine Years in a Japanese Local Community

An evidence-based review of unoprostone isopropyl ophthalmic solution 0.15% for glaucoma: place in therapy

Glaucoma - Next Generation Therapeutics: Impossible to Possible

Contact Info

Product

Resources

About